Platform/Pipeline
We are harnessing a unique tumor-immune co-culture system fully integrated with CRISPR that will allow:
Discovery of cancer biomarker, synthetic lethality, and resistant mutations for immuno-oncology (I/O) drugs as well as other cancer drugs
Systematic discovery of novel cancer drug targets (both Tumor-intrinsic and I/O drug targets)
We Aspire to Revolutionize Cancer Drug Development
MEDiC’s Pipeline and Partnerships
Are you interested in developing first-in-class oncology drugs by harnessing the novel targets offered through the MEDiC platform? Or have you already developed therapeutic drugs seeking to identify novel biomarkers for the drug, or to discover biomarkers linked to drug-resistant mutations for drug-resistant patient populations? MEDiC is ready to discuss a variety of different collaboration possibilities across MEDiC's platform partnerships and drug co-development programs. Please contact us at info@medicls.com and let us know how we can work together.